We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New Software Streamlines, Reduces Costs to Develop and Market Medical Device Technologies

By LabMedica International staff writers
Posted on 30 Apr 2009
Preliminary due diligence and fund development of new medical device technologies can cost up to US$75,000 and take up to three months. More...
But innovators, device manufacturers, service providers, venture capital firms, researchers, healthcare providers, and others now have access to a new online membership community with software that shortens this process to about 90 minutes for only a few thousand dollars, according to the software developer.

E-Zassi (Fernandina, FL, USA) Chief Executive Officer Peter M. von Dyck, remarked, "Not knowing critical details can dramatically hinder a technology from being successfully funded, licensed, developed, or commercialized." These critical details, according to Mr. von Dyck, include: a new technology's probable regulatory classifications; the associated clinical endpoints to support the safety and marketing claims to earn market clearances; early stage clarity on the reimbursement and market landscape; and identification of material manufacturing, distribution, and sales burdens.

E-Zassi dot com is predictive decision-support software that provides rapid due diligence, triaging, and assessment of new medical device innovations. Members can extract critical technical and business-related traits and attributes for a deep analysis and forecast of the opportunities and potential challenges that may be encountered from time of invention throughout all development and commercialization phases. Development and commercially related outputs that are critical include: technology transfer; business development; market and commercial analysis; due diligence and portfolio management; intellectual property and patent development; product development and financial planning; and capital acquisition via venture capital and grants.

All e-Zassi online elements are uniquely categorized and organized among thousands of Device Network Attributes (DNA) the company identified over several years. "We now know how this business and technology 'DNA' can be leveraged by the members in the e-Zassi community to rapidly identify synergistic partners and technologic opportunities," stated Mr. von Dyck. "Empowering our members to leverage these vital attributes on a private online community materially enhances search/match relevancy on a level not available on any other existing network, which helps lower costs, save time, and enhance success rates."

E-Zassi.com is a subscription-based online community and Software as a Service (SaaS) company that was spun off Zassi Medical Evolutions, a privately held company focused on innovation and development in medical devices.

Related Links:

e-Zassi



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Immunofluorescence Analyzer
IFA System
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.